Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.35 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.34 |
| ▸ | RORC | P51449 | 1/20 | 0.33 |
| ▸ | TACR3 | P29371 | 1/20 | 0.33 |
| ▸ | QDPR | P09417 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22031273 | 0.81 | HSD11B1 (0.39) | HSD11B1SMN1; SMN2KMT2A | |
| SCHEMBL22031235 | 0.80 | HSD11B1 (0.38) | HSD11B1SMN1; SMN2ALDH1A1 | |
| SCHEMBL21738111 | 0.79 | HRH3 (0.46) | EPHX1RIPK1RORCQDPREPHX2 | |
| SCHEMBL20160411 | 0.79 | PIK3CD (0.41) | HSD11B1SMN1; SMN2KMT2AALDH1A1 | |
| SCHEMBL22812224 | 0.78 | HSD11B1 (0.36) | HSD11B1SMN1; SMN2KMT2A | |
| SCHEMBL16456476 | 0.77 | SMN1; SMN2 (0.37) | HSD11B1SMN1; SMN2 | |
| SCHEMBL21159142 | 0.77 | RET (0.36) | HSD11B1SMN1; SMN2KMT2AALDH1A1 | |
| SCHEMBL23555271 | 0.73 | RET (0.35) | HSD11B1SMN1; SMN2KMT2ARIPK1 | |
| SCHEMBL20160449 | 0.73 | RET (0.34) | HSD11B1SMN1; SMN2KMT2A | |
| SCHEMBL20682392 | 0.72 | SMN1; SMN2 (0.40) | HSD11B1SMN1; SMN2EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220402910-A1 | THIADIAZOLE IRAK4 INHIBITORS | GILEAD SCIENCES, INC. | 2022-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220402910-A1 | THIADIAZOLE IRAK4 INHIBITORS | IRAK4, IRAK3, IRAK1 | HSD11B1 851/4885SMN1; SMN2 1294/4885KMT2A 551/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.